Boehringer Ingelheim Underscores Mental Health, COVID-19 In R&D Pipeline
While Jardiance Sales Keep Rising
Executive Summary
Germany’s Boehringer Ingelheim highlighted its clinical-stage research efforts in neuropsychiatry and COVID-19 when describing its first half financial results as solid, despite the continuing impact of the pandemic.